PMID- 28641483
OWN - NLM
STAT- MEDLINE
DCOM- 20180806
LR  - 20180806
IS  - 1973-9478 (Electronic)
IS  - 1120-009X (Linking)
VI  - 30
IP  - 1
DP  - 2018 Feb
TI  - Good performance of platinum-based chemotherapy for high-grade 
      gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
PG  - 53-58
LID - 10.1080/1120009X.2017.1340127 [doi]
AB  - To evaluate efficacy and safety of platinum and etoposide combination in the 
      treatment of advanced gastroenteropancreatic (GEP) and unknown primary (CUP) 
      neuroendocrine carcinomas (NEC), we analysed the records of 21 consecutive 
      patients treated with this regimen from 1999 to 2012. Objective responses were 
      obtained in 11 patients (52%) and disease stability (DS) in 5 (24%). Median 
      progression-free survival (PFS) was 7 months (95% CI, 5.33-8.66). Median overall 
      survival (OS) was 16 months (95% CI, 14.97-17.03). Patients with limited liver 
      disease had a significantly (p = 0.002) better PFS than patients with 
      extrahepatic disease at diagnosis with 9 months (95% CI, 7.14-10.85) vs. 4 months 
      (95% CI, 1.60-6.40). Two patients experienced durable complete response (30 and 
      90 months). The most common grade 3-4 toxicities were neutropenia (61%), anaemia 
      (50%), nausea and vomiting (27%) and fatigue (22%). The platinum plus etoposide 
      regimen has an acceptable toxicity profile and is effective in patients with GEP 
      and CUP-NECs.
FAU - Brandi, Giovanni
AU  - Brandi G
AD  - a Department of Experimental, Diagnostic and Speciality Medicine , 'L. & A. 
      Seragnoli' Institute of Hematology and Medical Oncology, Sant'Orsola-Malpighi 
      Hospital , Bologna , Italy.
AD  - b Interdepartmental Center for Cancer Research (CIRC) , Sant'Orsola-Malpighi 
      Hospital , Bologna , Italy.
FAU - Paragona, Marco
AU  - Paragona M
AD  - a Department of Experimental, Diagnostic and Speciality Medicine , 'L. & A. 
      Seragnoli' Institute of Hematology and Medical Oncology, Sant'Orsola-Malpighi 
      Hospital , Bologna , Italy.
FAU - Campana, Davide
AU  - Campana D
AD  - c Internal Medicine Unit, Medical and Surgical Sciences Department , 
      Sant'Orsola-Malpighi Hospital , Bologna , Italy.
FAU - Brighi, Nicole
AU  - Brighi N
AD  - a Department of Experimental, Diagnostic and Speciality Medicine , 'L. & A. 
      Seragnoli' Institute of Hematology and Medical Oncology, Sant'Orsola-Malpighi 
      Hospital , Bologna , Italy.
FAU - Bondi, Arrigo
AU  - Bondi A
AD  - d Cytological and Pathological Anatomy Unit , Maggiore Hospital , Bologna , 
      Italy.
FAU - Pantaleo, Maria Abbondanza
AU  - Pantaleo MA
AD  - a Department of Experimental, Diagnostic and Speciality Medicine , 'L. & A. 
      Seragnoli' Institute of Hematology and Medical Oncology, Sant'Orsola-Malpighi 
      Hospital , Bologna , Italy.
AD  - b Interdepartmental Center for Cancer Research (CIRC) , Sant'Orsola-Malpighi 
      Hospital , Bologna , Italy.
FAU - Corbelli, Jody
AU  - Corbelli J
AD  - a Department of Experimental, Diagnostic and Speciality Medicine , 'L. & A. 
      Seragnoli' Institute of Hematology and Medical Oncology, Sant'Orsola-Malpighi 
      Hospital , Bologna , Italy.
FAU - Barbera, Maria Aurelia
AU  - Barbera MA
AD  - a Department of Experimental, Diagnostic and Speciality Medicine , 'L. & A. 
      Seragnoli' Institute of Hematology and Medical Oncology, Sant'Orsola-Malpighi 
      Hospital , Bologna , Italy.
FAU - Biasco, Guido
AU  - Biasco G
AD  - a Department of Experimental, Diagnostic and Speciality Medicine , 'L. & A. 
      Seragnoli' Institute of Hematology and Medical Oncology, Sant'Orsola-Malpighi 
      Hospital , Bologna , Italy.
AD  - b Interdepartmental Center for Cancer Research (CIRC) , Sant'Orsola-Malpighi 
      Hospital , Bologna , Italy.
LA  - eng
PT  - Journal Article
DEP - 20170622
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - BG3F62OND5 (Carboplatin)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carboplatin/*administration & dosage/adverse effects
MH  - Carcinoma, Neuroendocrine/*drug therapy/mortality/pathology
MH  - Cisplatin/*administration & dosage/adverse effects
MH  - Disease-Free Survival
MH  - Etoposide/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Intestinal Neoplasms/drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasms, Unknown Primary/drug therapy/mortality
MH  - Pancreatic Neoplasms/drug therapy/mortality/pathology
MH  - Retrospective Studies
MH  - Stomach Neoplasms/drug therapy/mortality/pathology
OTO - NOTNLM
OT  - Chemotherapy
OT  - Etoposide
OT  - Gastroenteropancreatic neuroendocrine neoplasms
OT  - High-grade neuroendocrine tumors
OT  - Neuroendocrine carcinomas
OT  - Platinum
OT  - Unknown primary neuroendocrine neoplasms
EDAT- 2017/06/24 06:00
MHDA- 2018/08/07 06:00
CRDT- 2017/06/24 06:00
PHST- 2017/06/24 06:00 [pubmed]
PHST- 2018/08/07 06:00 [medline]
PHST- 2017/06/24 06:00 [entrez]
AID - 10.1080/1120009X.2017.1340127 [doi]
PST - ppublish
SO  - J Chemother. 2018 Feb;30(1):53-58. doi: 10.1080/1120009X.2017.1340127. Epub 2017 
      Jun 22.